Clinical Trials Logo

GM2 Gangliosidosis clinical trials

View clinical trials related to GM2 Gangliosidosis.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05758922 Active, not recruiting - Clinical trials for Niemann-Pick Disease, Type C

Phase 2 Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AZ-3102 in Patients With GM2 Gangliosidosis or Niemann-Pick Type C Disease

RAINBOW
Start date: April 24, 2023
Phase: Phase 2
Study type: Interventional

This phase 2 is a randomized, double-blind, placebo controlled, 12 weeks study with daily oral administration of AZ-3102 aiming to evaluate the safety and pharmacokinetic (PK) profile in GM2 Gangliosidosis and Niemann-Pick type C disease (NP-C) patients. If approved by the country health authorities, a double-blind extension period will be proposed to the patients who complete the 12-week study.

NCT ID: NCT02851862 Active, not recruiting - GM2 Gangliosidosis Clinical Trials

A Natural History of Late Onset Tay-Sachs Disease

Start date: April 2016
Phase:
Study type: Observational [Patient Registry]

The purpose of this study is to learn more about the natural history of Late Onset GM2 Gangliosidosis (Tay-Sachs disease and Sandhoff Disease) to inform future clinical trials.

NCT ID: NCT02699190 Active, not recruiting - Clinical trials for Adrenoleukodystrophy

LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies

Start date: January 6, 2017
Phase:
Study type: Observational

Leukodystrophies, and other heritable disorders of the white matter of the brain, were previously resistant to genetic characterization, largely due to the extreme genetic heterogeneity of molecular causes. While recent work has demonstrated that whole genome sequencing (WGS), has the potential to dramatically increase diagnostic efficiency, significant questions remain around the impact on downstream clinical management approaches versus standard diagnostic approaches.